

Press Release
27 January 2021 08:00:00 CET



Newbury Pharmaceuticals enters the Nordics with exciting product portfolio

Newbury Pharmaceuticals AB has signed a license agreement for 11 new products.

The agreement is part of Newbury's long-term strategy to build a pipeline of proprietary and licensed products to become a leading hybrid pharmaceutical company for specialty prescription drugs, innovation and brands with focus on the Scandinavian markets.

The new products belong to a variety of therapeutic categories including Atherothrombotic Events, Anxiety disorders, Benign Prostatic Hyperplasia, Cancer, Deep Vein Thrombosis and Systematic Embolism, Diabetes, Multiple Sclerosis, Multiple Myeloma and Primary Nocturnal Enuresis and includes patented formulation, a sophisticated medical device in the form of a pre-filled multidose pen as well as novelty value added delivery systems. The target markets are Sweden, Denmark and Norway and the products have an aggregated market value of SEK 3.1 billion.

The products will be launched gradually from 3rd quarter of 2021.

For mote information contact:

Karl Karlsson, Founder, Executive Chairman
karl.karlsson@newburypharma.com
Mobil: +46-46-121 120

www.newburypharma.com

About Newbury Pharmaceuticals

Newbury Pharmaceuticals is building a pipeline of proprietary and licensed products with focus on specialty and branded products in the Nordics. Newbury Pharmaceuticals wants to make a difference by offering treatment solutions within areas like oncology, rare diseases and neurology. The portfolio is built by leveraging its experience and extensive international network whereby Newbury can offer strategic partnerships of innovation for the benefit of the Nordic healthcare market.